Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Strategic Plan: Milestones Will Be Unveiled In June

This article was originally published in The Tan Sheet

Executive Summary

FDA plans to outline milestones for implementing a strategic action plan in a document slated for release by early June

You may also be interested in...



FDA Oversight Among Hot Button Issues In 112th Congress

Health care reform and oversight of FDA remain hot button issues in the 112th Congress, industry advocates say.

FDA Strategic Plan: Outsourcing Reviews For One-Third Of FTEs By 2006

FDA expects to complete reviews of competitive outsourcing opportunities for certain accounting and clerical services by the end of fiscal year 2004

FDA Strategic Plan: Outsourcing Reviews For One-Third Of FTEs By 2006

FDA expects to complete reviews of competitive outsourcing opportunities for certain accounting and clerical services by the end of fiscal year 2004

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel